China has announced a US$3.49 million (R60 million) partnership with South Africa to expand HIV prevention services among adolescents and young people, as ...
The Chinese funding comes as limiting the number of new infections has become increasingly difficult, with adolescent girls ...
Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
China will finance HIV-prevention programs in South Africa for the first time, taking a small step into the massive void left by US funding cuts earlier this year.
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
China has pledged $3.49m to support HIV prevention services in South Africa over the next two years under a new partnership ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback